Back to Search Start Over

Menopausal hormone therapy for primary prevention: why the USPSTF is wrong.

Authors :
Langer RD
Simon JA
Pines A
Lobo RA
Hodis HN
Pickar JH
Archer DF
Sarrel PM
Utian WH
Source :
Climacteric : the journal of the International Menopause Society [Climacteric] 2017 Oct; Vol. 20 (5), pp. 402-413. Date of Electronic Publication: 2017 Aug 14.
Publication Year :
2017

Abstract

The US Preventive Services Task Force (USPSTF) Draft Recommendation statement on Menopausal Hormone Therapy: Primary Prevention for Chronic Diseases, released in May 2017, perpetuates a major disconnect between the primary population affected, women within roughly 10 years of menopause, and the data cited. Furthermore, major elements of the evidence relied upon have been misinterpreted or misstated, particularly in regard to coronary heart disease and breast cancer, for which there is no statistically significant evidence of harm. As currently drafted, the recommendations reiterate the USPSTF statements of 2012, 2005 and 2002, and will perpetuate egregious harm to the public health. In an attempt to avoid that outcome and to facilitate a return to rational discourse regarding menopausal hormone therapy, an ad hoc group of experts in menopausal health submitted this comprehensive response to the USPSTF.

Details

Language :
English
ISSN :
1473-0804
Volume :
20
Issue :
5
Database :
MEDLINE
Journal :
Climacteric : the journal of the International Menopause Society
Publication Type :
Academic Journal
Accession number :
28805475
Full Text :
https://doi.org/10.1080/13697137.2017.1362156